Latest News and Press Releases

Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced the advancement of its aggressive “Go to Market” strategy for expansion of SofPulse® medical...

Expands Patient Education, Access to Non-Opioid Options for Pain Management Los Angeles, CA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced the...

Highlights its previously-announced “Build Up Strategy” of acquiring complementary specialty service providers in the construction industry  Los Angeles, CA, Nov. 07, 2022 (GLOBE NEWSWIRE) --...

LOS ANGELES, CA, April 25, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB:ENDV) today announced an agreement with NAMSA – a leading Global Contract Research Organization (CRO) and...

Los Angeles, CA, April 11, 2022 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) today announced significant advancement in the of process to obtain medical reimbursements for its...

High-Growth Acquisition Approaches Completion, Expected To Augment Core Business And Drive Long-Term Shareholder Value Los Angeles, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc....

Los Angeles, CA, May 11, 2021 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced completion of Shipment of SofPulse® tPEMF Devices for use in...

LOS ANGELES, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced financial and operating results for the second quarter ended...

Los Angeles, CA, June 01, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the signing of a Sales and Strategic Partnership Agreement...

Los Angeles, CA, May 04, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today reported financial results for fiscal year ended December 31, 2019. ...